Category Archives: Psyche Ward

CCHR NEWSLETTER: Psychiatric Inpatients Have Elevated Risks for Adverse Reactions

Psychiatric Inpatients Have Elevated Risks for Adverse Reactions

 

[Reference: “Multiple adverse outcomes following first discharge from inpatient psychiatric care: a national cohort study”, The Lancet Psychiatry, June 03, 2019]

People discharged from inpatient psychiatric care are at higher risk than the rest of the population for a range of serious fatal and non-fatal adverse outcomes.

These individuals are also more likely to perpetrate violent crimes, including homicide. Suicide risk is known to be especially raised soon after discharge.

READ NEWSLETTER

VLA commewnt:

I would encourage eveRyone to go to our pharmacogenetic “room”.  Millions of inpatients are being given  modern drugs for diagnoses of Bipolar, ADHD that they can’t metabolize.  By giving the inpatients drugs that are cookie cutter prescribed without the duty to care genetic test to see if the drug they are being prescribed can be adequately metabolized.  Cultural groups such as Caucasian, African Americans, Asians have different panels of enyzmes per culture.  For example 10% of Caucasians are genetically missing the liver enzyme that metabolized common psychiatric drugs such as Haldol, Respiradol, Adderall and street drugs such as cocaine, psyilosybn, LSD, etc.  When given cookie cutter prescriptions, taken on a daily  basis,  this demographic begin to have suicidal or homicidal ideations because the drug is accumulating in the body, not able to transduce by enzymatic activity into a harmless substance to be excreted out by the kidneys.

 

FDA Approves electroshock device for kids 7-12 who have been diagnosed as ADHD

The U.S. Food and Drug Administration (FDA) approved on April 19, 2019 a medical device for so-called attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System from NeuroSigma, is for patients ages 7 to 12 years old who are not currently taking prescription ADHD drugs.

This device delivers an electric current to the brain (through the V1 branch of the 5th cranial nerve) with an electrode taped to the forehead. It costs about $900 to start, with additional costs for more of the electrode patches which are only used once each. It is not currently reimbursed by insurance.    READ MORE…

VLA Comment: Well here we are Humanity…little lab rats!  Poison them kids, dogs and
plants too (vaccines, gmo food, geoengineering, fluoride, pesticides,
herbicides) them-disable them-electrocute them…and the new infanticide
bills…kill them immediately)*

Cytochrome P450: Physiological and pharmacological role in Mental Illness, Cancer, Parkinson

Suicides and homicides data

Images of School shooters

The cytochrome P450 isoenzymes are a superfamily of enzymes found in the Liver and in all cells except the blood.  These enzymes catalyse the metabolism of a large number of endogenous and exogenous compounds-prescription drugs and street drugs.

The vast individual variation of genetics vary greatly according to race and ethnicity.  It is the field of PHARMACOGENETICS that accounts for surge in “apparent” mental illness, suicides, drug addiction and homicides and disease susceptibility.

About 5–10% of Caucasians and 0.9% ofAsians metabolise debrisoquine and other substrates of CYP2D6 at a markedly decreased rate. In addition to thepoor and extensive metabolisers, a group called the ultrarapid metabolisers has been identified.

The CYP2C19 enzyme is also associated with genetic polymorphism. Slow metabolisers  are found in 2–5% of Caucasians, about20% of the Japanese population, 19% of African Americansand 8% of Africans [18].

Cytochrome P450: Physiological and pharmacological role READ THIS Study:

READ ALL OUR POSTS ON PHARMACOGENETICS

 

Killer Drugs? Homicide Risk Linked to Medications

Pharmacogenetics (gene testing): Attorney’s are now stepping up!

Medical DNA sequencing leads to lawsuits and legal questions

One of the biggest concerns is legal liability. Health care providers face a disconnect: Technology has outpaced their ability to interpret genetic results, such as a patient’s risk of breast cancer or heart attack from a particular mutation. Because of that, typical fallbacks including providing a rigorous standard of care—which can also act as a legal shield against malpractice claims—are becoming fuzzy. What is a doctor to do when a patient has results from a direct-to-consumer testing company like 23andMe and asks what implications they have for their health? Or when a lab notifies a doctor that a genetic variant their patient carries, thought meaningless 3 years ago, is now known to be harmful, but they can’t locate the patient? Can a testing lab be held liable for not regularly reviewing the scientific literature, to track science’s understanding of the gene variants it tests for?

Read more…

LawSeqSM: Building a Sound Legal Foundation for Translating Genomics into Clinical Application

This innovative 3-year project, based cooperatively at the University of Minnesota and Vanderbilt University, has convened a national Working Group of top legal and scientific experts to analyze current US federal and state law and regulation on translational genomics and to generate consensus guidance on what the law should be.

 

PHARMACOGENETIC TEST SIGNIFICANTLY INCREASE REMISSION OF MENTAL ILLNESS (DEPRESSION)

GeneSight employs a proprietary algorithm to analyze 12 genes and assess how they impact patients’ ability to process dozens of psychotropic medications. The test report buckets depression treatments as red (significant gene-drug interaction), yellow (moderate gene-drug interaction), or green (use as directed.) When the test report shows that patients are on red or yellow medications, their doctors should consider changing the drug or dose, while patients on green medications don’t require a medication change.

Researchers further evaluated patients who entered the study on red medications and either remained on red medications or were switched to yellow or green drugs. Remission rates were 153 percent higher, response rates were 71 percent higher, and symptom improvement rates were 59 percent higher when patients were switched from red to yellow or green meds — all statistically significant changes.

This analysis “establishes a new standard of care” for physicians by demonstrating that patients on red medications must be identified and have their medications modified, said Dechairo. “This switching analysis has also been an important point in our payor discussions, as utilization management programs can focus on switching patients from red medications, which would deliver results even better than those in the GUIDED study,” he said.

One prior cost-effectiveness study using drug claims data showed that using GeneSight can increase treatment adherence and save an average of $1,036 per year per patient, while another study using commercial claims data showed GeneSight’s potential to save $1,556 per patient by reducing disability claims, medical utilization, workplace absence.

Currently, the more than 300,000 GeneSight tests Myriad sells per year are largely ordered by psychiatrists. Once there is greater reimbursement traction, Myriad is planning a significant marketing push into the primary care market, including direct-to-patient advertising for the test, according to Capone.

GeneSight, which is a lab-developed test (LDT) performed in a CLIA-certified lab, must be ordered by physicians.

Capone noted that the FDA has publicly stated that it will continue to practice enforcement discretion for LDTs, and leave it up to legislators to reform diagnostic regulations that may or may not bring LDTs under the agency’s oversight. In December, legislators in the House of Representatives and the Senate incorporated the FDA’s ideas for diagnostics regulatory reform into a draft bill that features a pre-certification program that labs could use to bring the majority of new diagnostics to market, while having to submit around 10 percent of tests for premarket review.  READ MORE…

ABSTRACT OF STUDY

 

New Study: Vaccines linked to Increase in mass school shootings and suicides

New Study: Vaccines Linked to Decline in Mental Health and Social Interaction – A Cause of Increase in Mass School Shootings?

CCHR NEWSLETTER:  CAN VACCINES CAUSE PSYCHIATRIC DISORDERS?

The authors statistically analyzed insurance claims data between 2002 and 2007 for thousands of children ages 6 to 15 for any relationships between various vaccinations (influenza, tetanus & diphtheria, hepatitis A, hepatitis B, meningitis, varicella) and various subsequent psychiatric diagnoses (obsessive-compulsive disorder, anorexia nervosa, tic disorders, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder).

The overall conclusion of this analysis implies that the onset of some psychiatric disorders may be related to some children having recently received a vaccination.

READ NEWSLETTER…

Temporal Association of Certain Neuropsychiatric Disorders Following Vaccination of Children and Adolescents: A Pilot Case–Control Study

CCHR finds Study: Association of vaccines and psychiatric disorders in children and adolescents

Magic Mushrooms (Psilocybin) for Seniors

Psilocybin mushroom

Fungus

Description: A psilocybin mushroom is one of a polyphyletic group of fungi that contain any of various psychedelic compounds, including psilocybin, psilocin, and baeocystin. Common, colloquial terms for psilocybin mushrooms include psychedelic mushrooms, magic mushrooms, shrooms, and mush.

Johns Hopkins University studied psilocybin in particular and found that one-third of all participants reported that the experience was the single most spiritually significant moment of their lives and more than two-thirds reported it was among the top five most spiritually significant experiences. Two months after the study, 79% of the participants reported increased well-being or satisfaction; friends, relatives, and associates confirmed this. Read more…

VLA Comment and Warning:

10% of Caucasians and percentages of Asians and Blacks do not have the Liver enzyme, Cytochrome P450 2D6 necessary to metabolize psilocybin.  They become “psychotic”. 79% of the participants according to Hopkins Univ. experience increased well being.  What about the 21%?  Did they experience psychosis?  Every patient and every person in psychiatric drug testing should have their genetics tested prior to implementation.  A simple gene test is covered by medicare and medicaid.  See:

Depression/Anxiety: Professionals World Wide blame Aluminum in Vaccines!

 

Depression is on the rise around the world and, according to one author, the World Health Organization (WHO) has stated that approximately 300 million people worldwide suffer from this debilitating disorder

Author, Amy Morin, LCSW, wrote in her article, Depression Statistics Everyone Should Know, that in the United States alone, 16.2 million adults have experienced a major depressive episode in the past year.

Dr.Kelly Brogan’s  paper outlined the strong possibility that the aluminum adjuvant that is currently being used in at least 18 childhood vaccinations may be responsible for the increase in long-term brain inflammation, neurological complications and autoimmunity. She stated that:

“One of the most relevant aluminum-containing vaccines is Gardasil, responsible for more than 34000 reported adverse events,and now Gardasil 9, which contains twice the aluminum dose (ie, now with 500 μg per 3 recommended doses).”

READ MORE…